Skip to content

Effect of Solanum Melongena Extract in the Treatment of Arsenical Skin Lesion

Effect of Solanum Melongena Extract in the Treatment of Arsenical Skin Lesion

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03127670
Enrollment
30
Registered
2017-04-25
Start date
2016-11-14
Completion date
2017-12-31
Last updated
2018-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arsenical Keratosis

Brief summary

Solanum melongena is a common vegetable contains phytochemicals which prevent, reduce or delay the oxidation of DNA and alter the cellular signal transduction pathways controlling cell proliferation and apoptosis of human cancer. The skin of Solanum melongena peel contains nasunin an anthocyanins and chlorogenic acid which have anti-inflammatory, antioxidant, antimutagenic and antiangiogenic properties. Extract of Solanum melongena is used in actinic keratosis and Squamous cell carcinoma of the skin. This study will determine any change in arsenical skin lesion after administrating Solanum melongena extract cream.

Detailed description

Bangladesh is grappling with the world greatest ever environmental health disaster in history. About three decades, more than thirty millions people subsistence with this problem without any potential treatment. So, now arsenic crisis as a major issue and becomes a demand of era to find out the way to solve this problem. Chronic ingestion of arsenic contaminated water is a silent killer of the human because even it may cause death by carcinoma. Arsenic has an affinity to keratin-rich tissue like skin, hair, nail due to the presence of sulphydryl group, as a consequence, they manifest of clinical symptoms like hyperpigmentation or melanosis, diffuse dark brown spot of skin or characteristic rain drop appearance over the trunks, limbs; keratosis. Even due to prolong exposure to arsenic e.g. invasive skin lesion as Bown's disease and squamous cell carcinoma appear. Arsenic as neglected disease arsenic patients has no established treatment except preventive and supportive treatment of melanosis by drinking arsenic free water and salicylic acid as keratolytic substance. But the malignant condition of arsenic skin lesion treatment is not yet documented. Solanum melongena belongs to Leptostemonum Clade (the spine solanums) species-rice in solanaceae. It also called brinjal or eggplant. Solanum melongena is a common vegetable contains phytochemicals which prevent, reduce or delay the oxidation of DNA and alter the cellular signal transduction pathways controlling cell proliferation and apoptosis of human cancer. Polyphenols of Solanum melongena exhibit an anticancer effect both in vitro and in vivo experiments. Polyphenol reduces scavenge free radicals, induce apoptosis, inhibit cell proliferation and angiogenesis and exhibit phytoestrogen activity. On other hand, they suppress the NF-κB and the activating protein (AP-1), inhibit the mitogen-activated proteins (MAPKs), the protein kinase and growth factor receptor-mediated pathways which are involved in cell cycle arrest and possess anti-inflammatory properties. Solanum melongena has solasodine glycoalkaloids which are cytotoxic and bind with endogenous endocytic lectin of cancer cell membrane and induce apoptosis and cell death both in vivo and in vitro. The skin of Solanum melongena peel contains nasunin an anthocyanins and chlorogenic acid which have anti-inflammatory, antioxidant, antimutagenic and antiangiogenic properties. It has a cytotoxic effect on brine shrimp. Therefore, this study will be conducted to determine is there any change in the patient with arsenical skin lesions before and after application of topical Solanum melongena extract cream. Twenty-five patients with arsenical skin lesions will be recruited on the basis of inclusion and exclusion criteria after IRB approval. The patients will be applied Solanum melongena extract cream twice daily for 12 weeks without any interruption. Water and nails samples will be collected for confirming the diagnosis. Blood samples will be collected before and after treatment to evaluate the liver and renal function tests. So, this study will determine any change in arsenical skin lesion after administrating Solanum melongena extract cream.

Interventions

DRUGSolanum melongena peel extract 0.05%

Administered topically twice daily for 12 weeks

Sponsors

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Solanum melongena peel extract

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Age: 18-60 years * Sex: Both male and female * Arsenicosis: Severe arsenical skin lesions with Bowen's disease or Squamous cell carcinoma * Drinking arsenic contaminated water (\> 50 µg/L) for more than 6 months * Patient voluntarily agreed to participate * Patient who understood the instruction of applying medicine and apply it as he or she will be instructed

Exclusion criteria

* Age: Less than 18 and above 60 years * Expectant, Pregnant and lactating mother * Major health problems Tuberculosis, Hepatic diseases, Renal diseases, Systamic lupus erythrometosis, * Rheumatoid arthritis * Patient with other skin diseases like ectopic dermatitis, psoriasis, eczema, drug allergy * Food allergy of Solanum melongena * Patient who received treatment within last three months * Patient with Bowen disease and Squamous cell carcinoma due to other cause * Patient did not voluntarily agree to participants

Design outcomes

Primary

MeasureTime frameDescription
Changes in palmer arsenical keratosisClinical outcome [Time Frame:[0 week (baseline),12 weeks (end)] [Safety Issue: No]] [Safety Issue: No]]Size of keratotic lesion will be decreased

Secondary

MeasureTime frameDescription
Changes in the liver function testChange in lesion size [ Time Frame: [0 week (baseline), 12 weeks (end)] [Safety Issue: No]] [Safety Issue: No]]Abnormal liver function tests will be returned toward normal

Countries

Bangladesh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026